Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

This study has been terminated.
(Study was terminated due to patient complications unrelated to study drugs)
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Jill Bashutski, University of Michigan
ClinicalTrials.gov Identifier:
NCT01279187
First received: January 18, 2011
Last updated: April 20, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2015
  Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)